EcoDrugPlus

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSPNAG00000022596
Gene Symbol: LOC108444077
2 Cross references
175 Possible Orthologues:

Group 10 Secretory Phospholipase A2-Like

Ensembl ID : ENSPNAG00000010953
Gene Symbol: LOC108433143
3 Cross references
231 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSPNAG00000006608
Gene Symbol: GHRHR
2 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSPNAG00000006279
Gene Symbol: GHSR
3 Cross references
144 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSPNAG00000000902
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSPNAG00000022092
Gene Symbol: GUCY1A2
4 Cross references
203 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSPNAG00000008322
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSPNAG00000002080
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha

Ensembl ID : ENSPNAG00000020617
Gene Symbol: LOC108411456
3 Cross references
345 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSPNAG00000020599
Gene Symbol: LOC108411468
3 Cross references
330 Possible Orthologues:

High Mobility Group Protein B1-Like

Ensembl ID : ENSPNAG00000001250
Gene Symbol: LOC108433790
3 Cross references
509 Possible Orthologues:

High Mobility Group-T Protein-Like

Ensembl ID : ENSPNAG00000011332
Gene Symbol: LOC108439208
3 Cross references
511 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).